Product Description
SynDevRxs lead compound, evexomostat (SDX-7320), is the first therapy being developed specifically to treat cancer patients who are also overweight or have systemic metabolic dysfunction.
Mechanisms of Action: METAP2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: SynDevRx
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer|Hyperglycemia|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| The ARETHA Study | P2 |
Recruiting |
Triple Negative Breast Cancer |
2027-10-01 |
12% |
2022-10-07 |
Primary Endpoints |
| Amelia-1 | P2 |
Recruiting |
Hyperglycemia|Breast Cancer |
2026-03-01 |
12% |
2022-10-26 |
Primary Endpoints|Start Date|Treatments|Trial Status |